Iradimed Co (IRMD)

Nov 3, 2026

IRADIMED (IRMD) shares have gained attention following the release of their third-quarter 2026 results, new guidance, and a reaffirmed dividend. While the stock has seen a recent 3.57% gain, its 30-day and year-to-date returns are down, contrasting with strong longer-term performance. The article explores different valuation perspectives, including an "undervalued" narrative based on a new MRI-compatible IV pump and a "P/E lens" view suggesting the stock is richly valued.

Oct 30, 2026

iRadimed (NASDAQ: IRMD) reported record Q3 2026 revenue of $24.2 million, a 14% year-over-year increase, primarily driven by strong sales and ramped production of its new 3870 MR IV pump and 3880 monitor. The company achieved GAAP earnings of $0.51 per share and non-GAAP earnings of $0.55 per share, with gross margins improving to 76%. Management expressed confidence in continued growth, expecting double-digit revenue increases for 2027 and a strong finish to 2026, with Q4 revenue projected between $25 million and $26.5 million.